SCHEDULE 13G/A: Newpath Partners Reduces Stake in Prime Medicine to 4.7%

Newpath Partners, L.P. and its affiliated entities, including board member Thomas Cahill, have reported a beneficial ownership of 4.7% in Prime Medicine, Inc. common stock as of December 31, 2024, indicating a reduction from a previous filing.

Summary

• The filing is an Amendment No. 1 to Schedule 13G, indicating a change in beneficial ownership from a prior filing.
• The reporting persons are Newpath Partners, L.P., Newpath Partners GP, L.P., Newpath Partners GP, LLC, and Thomas Cahill.
• As of December 31, 2024, the reporting persons collectively beneficially own 6,105,679 shares of Prime Medicine, Inc. Common Stock.
• This ownership represents 4.7% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 131,160,842 shares of Common Stock outstanding as of December 5, 2024, as reported by Prime Medicine, Inc. in its Form S-3.
• The reporting persons hold shared voting power and shared dispositive power over all 6,105,679 shares.
• Thomas Cahill, a member of Prime Medicine, Inc.'s board of directors, is the managing member of Newpath GP LLC, which is the general partner of Newpath Partners GP, L.P., which in turn is the general partner of Newpath Partners, L.P.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by a significant investor group, including a board member, to below the 5% threshold, which could be perceived as a slightly negative signal regarding their conviction or a strategic portfolio adjustment.

Positives

• A significant institutional investor group, including a board member, continues to hold a substantial stake of 4.7% in Prime Medicine, Inc., indicating continued, albeit reduced, investment.

Negatives

• The reduction in beneficial ownership to below 5% suggests that Newpath Partners and its affiliates have decreased their stake in Prime Medicine, Inc. from a previous filing where they likely held 5% or more.

Related Party Transactions

• Thomas Cahill, a member of Prime Medicine, Inc.'s board of directors, is the managing member of Newpath GP LLC, which controls the Newpath Partners entities that beneficially own the shares.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by a significant investor group, including a board member, as a signal of reduced confidence or a portfolio rebalancing, potentially influencing investor sentiment.

Key Dates

Recommendation

Keywords

Prime Medicine, Newpath Partners, Thomas Cahill, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Stake Reduction